Relevant Adverse Events and Drug Discontinuation of Sacubitril/Valsartan in Patients with Transthyretin Amyloid Cardiomyopathy - Insights from the REVIEW-HF Registry

Q: What does this research mean for the field?

Sacubitril/valsartan has a specific safety and tolerability profile regarding adverse events and drug discontinuation in patients with transthyretin amyloid cardiomyopathy. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Yukihiro Watanabe; Yoshiaki Kubota; Hiroshige Murata; Saori Uchiyama; Kuniya Asai; Takahito Nasu; Shunsuke Ishii; Nobuyuki Kagiyama; Keisuke Kida; Wataru Fujimoto; Atsushi Kikuchi; Takeshi Ijichi; Tatsuhiro Shibata; Koshiro Kanaoka; Shingo Matsumoto

doi:10.1536/ihj.25-686

January 1, 2026International Heart JournalOpen Access

Relevant Adverse Events and Drug Discontinuation of Sacubitril/Valsartan in Patients with Transthyretin Amyloid Cardiomyopathy - Insights from the REVIEW-HF Registry

View Full Paper

Ask AI

Bookmark

Share

Key Points

Assess the safety profile and tolerability of sacubitril/valsartan in patients with transthyretin amyloid cardiomyopathy.
Analyzed data from the REVIEW-HF registry
Focused on adverse events and rates of drug discontinuation
Population included patients diagnosed with ATTR-CM
Identified key adverse events associated with sacubitril/valsartan use
Determined drug discontinuation rates among patients
Provided insights into the overall tolerability of the treatment

Abstract

Data on the safety and tolerability of sacubitril/valsartan in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are limited.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Watanabe et al. (2026) studied this question.

synapsesocial.com/papers/6a0aabc25ba8ef6d83b6f843 https://doi.org/10.1536/ihj.25-686

View Full Paper

Ask AI

Bookmark

Share

Relevant Adverse Events and Drug Discontinuation of Sacubitril/Valsartan in Patients with Transthyretin Amyloid Cardiomyopathy - Insights from the REVIEW-HF Registry

Key Points

Abstract

Discussion

Cite This Study

Relevant Adverse Events and Drug Discontinuation of Sacubitril/Valsartan in Patients with Transthyretin Amyloid Cardiomyopathy - Insights from the REVIEW-HF Registry

Key Points

Abstract

Discussion

Cite This Study

Keep reading

Keep reading